- Home
- CVNA vs ARGX Comparison
CVNA vs ARGX Comparison
Compare CVNA & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVNA
- ARGX
- Stock Information
- Founded
- CVNA 2012
- ARGX 2008
- Country
- CVNA United States
- ARGX Netherlands
- Employees
- CVNA N/A
- ARGX N/A
- Industry
- CVNA Other Specialty Stores
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVNA Consumer Discretionary
- ARGX Health Care
- Exchange
- CVNA Nasdaq
- ARGX Nasdaq
- Market Cap
- CVNA 36.7B
- ARGX 40.4B
- IPO Year
- CVNA 2017
- ARGX 2017
- Fundamental
- Price
- CVNA $166.61
- ARGX $581.21
- Analyst Decision
- CVNA Buy
- ARGX Strong Buy
- Analyst Count
- CVNA 18
- ARGX 20
- Target Price
- CVNA $264.78
- ARGX $682.00
- AVG Volume (30 Days)
- CVNA 5.4M
- ARGX 294.8K
- Earning Date
- CVNA 04-30-2025
- ARGX 05-08-2025
- Dividend Yield
- CVNA N/A
- ARGX N/A
- EPS Growth
- CVNA 112.61
- ARGX N/A
- EPS
- CVNA 1.59
- ARGX 12.78
- Revenue
- CVNA $13,673,000,000.00
- ARGX $2,252,039,000.00
- Revenue This Year
- CVNA $23.40
- ARGX $57.59
- Revenue Next Year
- CVNA $17.77
- ARGX $31.90
- P/E Ratio
- CVNA $104.72
- ARGX $42.38
- Revenue Growth
- CVNA 26.94
- ARGX 77.52
- 52 Week Low
- CVNA $67.61
- ARGX $349.86
- 52 Week High
- CVNA $292.84
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- CVNA 28.58
- ARGX 34.55
- Support Level
- CVNA $166.25
- ARGX $562.96
- Resistance Level
- CVNA $190.71
- ARGX $593.10
- Average True Range (ATR)
- CVNA 16.35
- ARGX 16.86
- MACD
- CVNA -6.85
- ARGX -4.90
- Stochastic Oscillator
- CVNA 4.03
- ARGX 20.78
About CVNA Carvana Co.
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.